Featured Articles
-
Ensuring Biomanufacturing Resilience For Biologics And Vaccines
10/19/2023
We highlight strategies for ensuring the reliable delivery of health technologies with a focus on vaccines, mAbs, and new modalities manufactured by biotechnology companies and institutes.
-
Improving The Characterization Of Gene Therapy Products
10/19/2023
The analysis of over 10 variant callers and other bioinformatics tools for viral variant detection are discussed to better understand how the outcomes can improve gene therapy product characterization.
-
Development Of A Novel Cell Culture Medium For AAV Production
9/26/2023
Explore the medium development process of a novel cell culture medium for AAV production with multiple HEK293 lineages, which was performed with three different HEK293 cell lines to maximize AAV titers.
-
Economics For Vaccine Manufacturing: Comparing Traditional To Modern Modalities
9/11/2023
Explore key points from the presentation MilliporeSigma delivered on the analysis and comparison of manufacturing costs between traditional and modern vaccines at the World Vaccine Congress Washington 2023.
-
Why Choosing A Client-Centric CTDMO Is Critical In Biomanufacturing
9/11/2023
Outsourcing to a CTDMO is a promising solution for companies lacking the technical expertise and in-house capacity to address biomanufacturing challenges. Learn why selecting the right CTDMO partner is vital for project success.
-
Eliminating USP <88> In Vivo Animal Bioreactivity Testing For Polymer Characterization
8/25/2023
There has been growing awareness about the environmental and ethical implications of plastics used in bioprocessing. The time for a shift to well-studied, proven in vitro cytotoxicity testing is now.
-
Optimizing The Formulation For A Monoclonal Antibody
8/21/2023
An emerging biotech company sought help developing a formulation for a monoclonal antibody. Explore how MilliporeSigma delivered an optimized formulation within an aggressive timeline and budget.
-
Market Watch And Perspectives On Vaccines Manufacturing In APAC
8/16/2023
Nearly forty biopharmaceutical companies, CDMOs, and research institute executives took part in interviews on the future of vaccine manufacturing. Explore the key findings following these interviews.
-
What The ICH Q5A Virus Safety Guidelines Mean For Your Cell & Gene Therapy Product
8/11/2023
Explore Cell & Gene therapy (CGT) products now within scope of the ICH Q5A guidance, technologies that can replace traditional testing strategies, viral clearance studies expected for vector products, and more.
-
The State Of Plastics Recycling In BioPharma
8/9/2023
Recycling plastics from biomanufacturing proves uniquely difficult due to circularity, quality, and infrastructure challenges. Nonetheless, change is underway. Learn how this change is being spearheaded by industry leaders.